Funding/support:
This work is supported by the National Natural Science Foundation of
China (82071730 to X.H.L and 82088102 to H.F.H), CAMS Innovation Fund
for Medical Sciences (2019-I2M-5-064 to H.F.H), Open Fund Project of
Guangdong Academy of Medical Sciences (YKY-KF202202 to H.F.H),
Collaborative Innovation Program of Shanghai Municipal Health Commission
(2020CXJQ01 to H.F.H), Clinical Research Plan of SHDC (SHDC2020CR1008A
to H.F.H and SHDC12019X17 to X.H.L), Shanghai Clinical Research Center
for Gynecological Diseases (22MC1940200 to H.F.H), Shanghai Urogenital
System Diseases Research Center (2022ZZ01012 to H.F.H), Shanghai
Frontiers Science Research Base of Reproduction and Development and the
Clinical Research Plan of IPMCH (IPMCH2022CR1-03 to D.D.W).
Role of the funder/sponsor: The funders had no role in the
design and conduct of the study; collection, management, analysis or
interpretation of the data; preparation, review or approval of the
manuscript; or the decision to submit the manuscript for publication.
Patient consent and approval: The authors have obtained both
informed written consent and ethics committee approval for studies on
patients and patient records.
REFERENCES
1. Hypertension in pregnancy. Report of the American College of
Obstetricians and Gynecologists’ Task Force on Hypertension in
Pregnancy. Obstet Gynecol. 2013;122(5):1122-31.
2. Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al.
Maternal mortality for 181 countries, 1980-2008: a systematic analysis
of progress towards Millennium Development Goal 5. Lancet.
2010;375(9726):1609-23.
3. Wanderer JP, Leffert LR, Mhyre JM, Kuklina EV, Callaghan WM, Bateman
BT. Epidemiology of obstetric-related ICU admissions in Maryland:
1999-2008*. Crit Care Med. 2013;41(8):1844-52.
4. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related
mortality in the United States, 1998 to 2005. Obstet Gynecol.
2010;116(6):1302-9.
5. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia
Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China.
JAMA Netw Open. 2021;4(5):e218401.
6. Li N, An H, Li Z, Ye R, Zhang L, Li H, et al. Preconception blood
pressure and risk of gestational hypertension and preeclampsia: a large
cohort study in China. Hypertens Res. 2020;43(9):956-62.
7. Coutinho T, Lamai O, Nerenberg K. Hypertensive Disorders of Pregnancy
and Cardiovascular Diseases: Current Knowledge and Future Directions.
Curr Treat Options Cardiovasc Med. 2018;20(7):56.
8. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All
Hypertensive Disorders of Pregnancy Increase the Risk of Future
Cardiovascular Disease. Hypertension. 2017;70(4):798-803.
9. Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova
D, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial:
influence of compliance on beneficial effect of aspirin in prevention of
preterm preeclampsia. Am J Obstet Gynecol. 2017;217(6):685 e1- e5.
10. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et
al. Prevention of preeclampsia and intrauterine growth restriction with
aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol.
2010;116(2 Pt 1):402-14.
11. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use
to Prevent Preeclampsia and Related Morbidity and Mortality: Updated
Evidence Report and Systematic Review for the US Preventive Services
Task Force. JAMA. 2021;326(12):1192-206.
12. Serra B, Mendoza M, Scazzocchio E, Meler E, Nolla M, Sabria E, et
al. A new model for screening for early-onset preeclampsia. Am J Obstet
Gynecol. 2020;222(6):608 e1- e18.
13. Del Vecchio G, Li Q, Li W, Thamotharan S, Tosevska A, Morselli M, et
al. Cell-free DNA Methylation and Transcriptomic Signature Prediction of
Pregnancies with Adverse Outcomes. Epigenetics. 2021;16(6):642-61.
14. Wu DD, Gao L, Huang O, Ullah K, Guo MX, Liu Y, et al. Increased
Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a
Low-Risk Cohort: Evidence From 47 874 Cases. Hypertension.
2020;75(3):772-80.
15. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison
Himmelfarb C, et al. 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure
in Adults: A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines. J Am Coll
Cardiol. 2018;71(19):e127-e248.
16. Bello NA, Zhou H, Cheetham TC, Miller E, Getahun DT, Fassett MJ, et
al. Prevalence of Hypertension Among Pregnant Women When Using the 2017
American College of Cardiology/American Heart Association Blood Pressure
Guidelines and Association With Maternal and Fetal Outcomes. JAMA Netw
Open. 2021;4(3):e213808.
17. Hu J, Li Y, Zhang B, Zheng T, Li J, Peng Y, et al. Impact of the
2017 ACC/AHA Guideline for High Blood Pressure on Evaluating Gestational
Hypertension-Associated Risks for Newborns and Mothers. Circ Res.
2019;125(2):184-94.
18. Sutton EF, Hauspurg A, Caritis SN, Powers RW, Catov JM. Maternal
Outcomes Associated With Lower Range Stage 1 Hypertension. Obstet
Gynecol. 2018;132(4):843-9.
19. Hauspurg A, Parry S, Mercer BM, Grobman W, Hatfield T, Silver RM, et
al. Blood pressure trajectory and category and risk of hypertensive
disorders of pregnancy in nulliparous women. Am J Obstet Gynecol.
2019;221(3):277 e1- e8.
20. Schechtman E. Odds ratio, relative risk, absolute risk reduction,
and the number needed to treat–which of these should we use? Value
Health. 2002;5(5):431-6.
21. Slade LJ, Mistry HD, Bone JN, Wilson M, Blackman M, Syeda N, et al.
American College of Cardiology and American Heart Association blood
pressure categories-a systematic review of the relationship with adverse
pregnancy outcomes in the first half of pregnancy. Am J Obstet Gynecol.
2023;228(4):418-29 e34.
22. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia
screening and prediction. Am J Obstet Gynecol. 2022;226(2S):S1071-S97
e2.
23. Force USPST, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey
AB, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and
Mortality: US Preventive Services Task Force Recommendation Statement.
JAMA. 2021;326(12):1186-91.
24. Xue RH, Wu DD, Zhou CL, Chen L, Li J, Li ZZ, et al. Association of
high maternal triglyceride levels early and late in pregnancy with
adverse outcomes: A retrospective cohort study. J Clin Lipidol.
2021;15(1):162-72.
25. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S,
et al. Hypertensive Disorders of Pregnancy: ISSHP Classification,
Diagnosis, and Management Recommendations for International Practice.
Hypertension. 2018;72(1):24-43.
26. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug
therapy for mild to moderate hypertension during pregnancy. Cochrane
Database Syst Rev. 2018;10:CD002252.
27. Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, et
al. Pregnancy Outcome After First Trimester Use of Methyldopa: A
Prospective Cohort Study. Hypertension. 2017;70(1):201-8.
28. Zetterstrom K, Lindeberg SN, Haglund B, Hanson U. Maternal
complications in women with chronic hypertension: a population-based
cohort study. Acta Obstet Gynecol Scand. 2005;84(5):419-24.
29. Bone JN, Magee LA, Singer J, Nathan H, Qureshi RN, Sacoor C, et al.
Blood pressure thresholds in pregnancy for identifying maternal and
infant risk: a secondary analysis of Community-Level Interventions for
Pre-eclampsia (CLIP) trial data. Lancet Glob Health.
2021;9(8):e1119-e28.
30. Hauspurg A, Sutton EF, Catov JM, Caritis SN. Aspirin Effect on
Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a
High-Risk Cohort. Hypertension. 2018;72(1):202-7.
31. McCarthy FP, Ryan RM, Chappell LC. Prospective biomarkers in preterm
preeclampsia: A review. Pregnancy Hypertens. 2018;14:72-8.
32. Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al.
Vital Signs: Pregnancy-Related Deaths, United States, 2011-2015, and
Strategies for Prevention, 13 States, 2013-2017. MMWR Morb Mortal Wkly
Rep. 2019;68(18):423-9.
33. He XJ, Dai RX, Hu CL. Maternal prepregnancy overweight and obesity
and the risk of preeclampsia: A meta-analysis of cohort studies. Obes
Res Clin Pract. 2020;14(1):27-33.
34. Alston MC, Redman LM, Sones JL. An Overview of Obesity, Cholesterol,
and Systemic Inflammation in Preeclampsia. Nutrients. 2022;14(10).
35. Spradley FT. Metabolic abnormalities and obesity’s impact on the
risk for developing preeclampsia. Am J Physiol Regul Integr Comp
Physiol. 2017;312(1):R5-R12.
36. Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, Crispi F, et
al. Atherogenic lipoprotein subfraction profile in preeclamptic women
with and without high triglycerides: different pathophysiologic subsets
in preeclampsia. Metabolism. 2005;54(11):1504-9.
37. Ziaei S, Bonab KM, Kazemnejad A. Serum lipid levels at 28-32 weeks
gestation and hypertensive disorders. Hypertens Pregnancy.
2006;25(1):3-10.
38. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, et
al. Association of lipid levels during gestation with preeclampsia and
gestational diabetes mellitus: a population-based study. Am J Obstet
Gynecol. 2009;201(5):482 e1-8.